N
Noam Benyamini
Researcher at Rambam Health Care Campus
Publications - 40
Citations - 985
Noam Benyamini is an academic researcher from Rambam Health Care Campus. The author has contributed to research in topics: Myeloid leukemia & Transplantation. The author has an hindex of 13, co-authored 38 publications receiving 762 citations. Previous affiliations of Noam Benyamini include Sapienza University of Rome.
Papers
More filters
Journal ArticleDOI
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos,Hilary Blacklock,Fredrik Schjesvold,Albert Oriol,David Simpson,Anupkumar George,Hartmut Goldschmidt,Alessandra Larocca,Asher Chanan-Khan,Daniel W. Sherbenou,Irit Avivi,Noam Benyamini,Shinsuke Iida,Morio Matsumoto,Kenshi Suzuki,Vincent Ribrag,Saad Z. Usmani,Sundar Jagannath,Enrique M. Ocio,Paula Rodriguez-Otero,Jesús F. San Miguel,Uma Kher,Mohammed Z.H. Farooqui,Jason J. Z. Liao,Patricia Marinello,Sagar Lonial,Andrew Nicol,George Grigoriadis,John Catalano,Richard Leblanc,Mohamed Elemary,Nizar J. Bahlis,Thierry Facon,Lionel Karlin,Michel Attal,Monika Engelhardt,Katja Weisel,Andreas Mackensen,Arnon Nagler,Dina Ben Yehuda,Hila Magen-Nativ,Antonio Palumbo,Michele Cavo,Kensei Tobinai,Takaai Chou,Hiroshi Kosugi,Masafumi Taniwaki,Kazutaka Sunami,Kiyoshi Ando,Peter Ganly,Bjorn Gjertsen,Juan J. Lahuerta,Joan Bladé,Albert Oriol Rocafiguera,Maria V. Mateos,Maria V. Mateos,Sarah Larson,Djordje Atanackovic,Srinivas Devarakonda,Jacob D. Bitran,Jeffrey A. Zonder,Neil Morganstein,Mohammad Hay,Gene Saylors,Ebenezer Kio,Ira Oliff,Dean Kirkel,Mikhail Shtivelband,Carrie Yuen,Andrew Yee,Jatin P. Shah,Myo Htut,Shahzad Raza,Saurabh Chhabra,Patrick J. Stiff,Parameswaran Hari,Bruce Bank,Ehsan Malek,Cristina Gasparetto,Ycaoub Faroun,William Kreisle,Seema Singhal,Jacalyn Rosenblatt,Saad Usmani,Saad Usmani,Wes Lee,Hana Safah,Jose Lutzky,Jason Suh,Dorothy Pan,Ari Baron,Robert Manges,Ronald Steis,Moacyr Oliveira,Jan S. Moreb,Natalie S. Callander,Bertrand Anz,Anastasios Raptis,Laura Stampleman,Jason Melear,Thomas E. Boyd,Lawrence Garbo,Leonard Klein,Spencer Shao,Roger M. Lyons,Kristi McIntyre,Stefano R. Tarantolo,Christopher Yasenchak,Habte A. Yimer +108 more
TL;DR: The FDA established that risks associated with the triple combination outweighed benefits and halted the study and presented an unplanned, ad-hoc interim analysis.
Journal ArticleDOI
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Z. Usmani,Fredrik Schjesvold,Albert Oriol,Lionel Karlin,Michele Cavo,Robert M Rifkin,Habte Aragaw Yimer,Richard Leblanc,Naoki Takezako,Robert Donald McCroskey,Andrew Lim,Kenshi Suzuki,Hiroshi Kosugi,George Grigoriadis,Irit Avivi,Thierry Facon,Sundar Jagannath,Sagar Lonial,Razi Ghori,Mohammed Z.H. Farooqui,Patricia Marinello,Jesús F. San-Miguel,Andrew Lim,Trish Walker,Andrew Nicol,Donna E. Reece,Mohamed Elemary,Jean Samuel Boudreault Pedneault,Michel Attal,Katja Weisel,Monika Engelhardt,Andreas Mackensen,John Quinn,Amos Cohen,Hila Magen-Nativ,Noam Benyamini,Alessandra Larocca,Morio Matsumoto,Shinsuke Iida,Takayuki Ishikawa,Yukio Kondo,Kazutaka Sunami,Kiyoshi Ando,Takanori Teshima,Takaaki Chou,Hiromi Iwasaki,Hirokazu Miki,Itaru Matsumura,Yasushi Onishi,Koji Izutsu,Masahiro Kizaki,Anupkumar George,Hillary Blacklock,David Simpson,Anders Waage,Olga Samoilova,Evgeniy Nikitin,Tatiana Chagorova,Andrew McDonald,Moosa Patel,Albert Oriol Rocafiguera,Jesus San Miguel Izquierdo,Maria V. Mateos,Matthew Streetly,Peter Forsyth,Graham Jackson,Stephen Jenkins,Robert M. Rifkin,Habte A. Yimer,Robert McCroskey,Danko Martincic,Stefano R. Tarantolo,Sarah Larson,Yacoub Faroun,Jennifer Vaughn,Rachid Baz,Gene Saylors,Amarendra K. Neppalli,Anastasios Raptis,Henry C. Fung,Maxwell Janosky,Don A. Stevens,Morton Coleman,Dennis Costa,Scott Cross,Suzanne Fanning,Daniel Farray Berges,Thomas Harris,Ira Zackon,Djordje Atanackovic,Kelvin Lee,Ira Oliff,Wes Lee,William I. Bensinger,Jose Lutzky,Ari Baron,Fadi Hayek,Eli Kirschner,Neeraj Bharany,Lindsay Overton,Siva Mannem,Allyson Harroff,Sharad Jain,Tammy Roque,Kristi McIntyre,Christopher K Yasencha,William Houck +106 more
TL;DR: The primary endpoint was progression-free survival, which was investigator-assessed because of early trial termination, and Efficacy was analysed in all randomly assigned patients and safety was analyses in all patients who received at least one dose of study drug.
Journal ArticleDOI
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
François Xavier Mahon,Carla Boquimpani,Dong-Wook Kim,Noam Benyamini,Nelma Cristina D. Clementino,Vasily Shuvaev,Sikander Ailawadhi,Jeffrey H. Lipton,Anna G. Turkina,Raquel De Paz,Beatriz Moiraghi,Franck E. Nicolini,Jolanta Dengler,Tomasz Sacha,Naoto Takahashi,Rafik Fellague-Chebra,Sandip Acharya,Stephane Wong,Yu Jin,Timothy P. Hughes +19 more
TL;DR: In this article, the authors evaluated treatment-free remission after discontinuation of second-line nilotinib therapy in chronic myeloid leukemia (CML) using a single-group, phase 2, open-label study.
Journal Article
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
Francois-Xavier Mahon,Carla Boquimpani,Dong-Wook Kim,Noam Benyamini,Nelma Cristina D. Clementino,Vasily Shuvaev,Sikander Ailawadhi,Jeffrey H. Lipton,Anna G. Turkina,Raquel De Paz,Beatriz Moiraghi,Franck E. Nicolini,Jolanta Dengler,Tomasz Sacha,Naoto Takahashi,Rafik Fellague-Chebra,Sandip Acharya,Stephane Wong,Yu Jin,Timothy P. Hughes +19 more
TL;DR: The ENESTcmr (Evaluating Nilotinib Efficacy and Safety in Clinical TrialsComplete Molecular Response) study demonstrated that switching to nilotinib may provide a path to achieving DMR, confirming the feasibility of TFR after sustained DMR in patients receiving TKIs.
Journal ArticleDOI
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era
Tamar Tadmor,Alessia Bari,Stefano Sacchi,Luigi Marcheselli,Eliana Valentina Liardo,Irit Avivi,Noam Benyamini,Dina Attias,Samantha Pozzi,Maria Christina Cox,Luca Baldini,Maura Brugiatelli,Massimo Federico,Aaron Polliack +13 more
TL;DR: A simple parameter such as absolute monocyte count (>630/mm3) can easily be used routinely in the evaluation of newly diagnosed diffuse large B-cell lymphoma to identify high-risk patients with a worse survival in the rituximab era.